1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
According to the recently published report 'Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020'; Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein is a plasma protein that promotes the transfer of cholesteryl esters from anti-atherogenic HDLs to proatherogenic apolipoprotein B (apoB)-containing lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs. A deficiency of CETP is associated with increased HDL levels and decreased LDL levels, a profile that is typically anti-atherogenic.
The report 'Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020' outlays comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders and Cardiovascular which include indications Dyslipidemia, Acute Coronary Syndrome and Cardiovascular Disease.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
- The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Introduction
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Development
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Assessment
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Companies Involved in Therapeutics Development
CKD-508 - Drug Profile
CKD-519 - Drug Profile
dalcetrapib - Drug Profile
HL-16 - Drug Profile
obicetrapib - Drug Profile
Small Molecule to Inhibit CETP for Cardiovascular Disease - Drug Profile
Small Molecule to Inhibit CETP for Dyslipidemia - Drug Profile
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Product Development Milestones
Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bristol-Myers Squibb Co
- Chong Kun Dang Pharmaceutical Corp
- DalCor Pharmaceuticals Inc
- NewAmsterdam Pharma BV